Fremont Bank Foundation Donates $750,000 to St. Rose Hospital Foundation

To Enhance Its Cardiac Catheterization Laboratory Equipment

Fremont Bank Foundation recently donated $750,000 to its community partner St. Rose Hospital Foundation for the hospital to purchase a new catalyst cardiac catheterization laboratory machine while keeping services available to Bay Area patients.

The innovative Philips Azurion 7 C20 replaces an older cardiac catheterization model recently rendered obsolete.

St. Rose Hospital Foundation regularly receives emergency transports of patients from its facility and other Bay Area hospitals who are suffering from heart attacks and are in need of lifesaving cardiac procedures. St. Rose Hospital, located in Hayward, Calif., is a STEMI (ST-elevation myocardial infarction) Receiving Center—a designation only given to hospitals where staff can meet rigorous standards of transferring a patient to the cardiac catheterization lab from the emergency room in 90 minutes or less.

“Health-care workers need access to the most state-of-the-art equipment in order to provide high-quality services to our patients,” said Michael Cobb, St. Rose Hospital Foundation Executive Director. “Fremont Bank Foundation’s generous contribution allows us to quickly replace an outdated machine while ensuring a seamless continuation of providing top care to the residents of Alameda County and beyond.”

Every year, St. Rose Hospital doctors and nurses perform, on average, more than 400 cardiac diagnostic procedures and manage over 200 STEMI emergencies. In 2021, catheterization laboratory personnel conducted upward of 2,600 non-urgent and emergent cardiac procedures.

“St. Rose Hospital is a vital part of our Alameda County ecosystem, and we really listened when its Foundation expressed the importance behind upgrading the catheterization lab machine,” said Brian Hughes, Fremont Bank Executive Vice President and Foundation President and Executive Director. “This significant gift is one that will keep serving the health of our Bay Area community for years to come.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”